Cellectis Granted Patent for CRISPR Use in T-Cells – Pharmaceutical Processing
Pharmaceutical Processing |
Cellectis Granted Patent for CRISPR Use in T-Cells
Pharmaceutical Processing EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1, for the genetic engineering of T-cells. The patent will be issued on August 2, 2017. This therapeutic-focused patent follows previous intellectual property that … Cellectis to receive European patent for CRISPR use in T-cells |
